HCV AMWMF Leitlinien Addendum Feb 2015 2014| Rolf Kaiser, Institut - PowerPoint PPT Presentation

Jan 10, 2024 •324 likes •403 views

HCV AMWMF Leitlinien Addendum Feb 2015 2014| Rolf Kaiser, Institut fr Virologie, Universitt zu Kln 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser

HCV AMWMF Leitlinien Addendum Feb 2015 2014| Rolf Kaiser, Institut für Virologie, Universität zu Köln
2014| Rolf Kaiser
2014| Rolf Kaiser
2014| Rolf Kaiser
2014| Rolf Kaiser
2014| Rolf Kaiser
2014| Rolf Kaiser

Recommend

HCV Treatment : SOTA : where are we today ? Robert G. Gish MD San Diego ACCP 2012 Concepts in

HCV Treatment : SOTA : where are we today ? Robert G. Gish MD San Diego ACCP 2012 Concepts in HCV HCV is curable 20-30% of HCV infected patient develop cirrhosis HCV is a systemic disease: note cyroglobulinemia HCV increases

789 views • 30 slides

HCV AND HEPATITIS HCV epidemiology and treatment failure Arevir meeting, 04.05.2019 | Saleta

HCV AND HEPATITIS HCV epidemiology and treatment failure Arevir meeting, 04.05.2019 | Saleta Sierra Geno2pheno [HCV] Team Geno2pheno [HCV] USAGE Geno2pheno [HCV] USAGE PEPSI Study in numbers 2882 Patienten 4759 Proben 46 DAA-therapy

635 views • 26 slides

HCV NS3/4A protease inhibitors for the treatment of HCV infected patients TMC435 Oliver

HCV NS3/4A protease inhibitors for the treatment of HCV infected patients TMC435 Oliver Lenz Tibotec BVBA, Beerse, Belgium; AREVIR-GenaFor-Meeting, Bonn 2011 Current HCV Treatment Goal = Sustained Virologic Response

449 views • 21 slides

POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant

ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES: HK SCENARIO N=1055 (1998-2004)

630 views • 40 slides

Geno2pheno[HCV] - Past, Present & Future Developments Bastian Beggel Max-Planck-Institute

Geno2pheno[HCV] - Past, Present & Future Developments Bastian Beggel Max-Planck-Institute for Informatics D-66123 Saarbrcken, Germany geno2pheno[HCV] geno2pheno[HCV] web-service for the analysis of HCV sequence data

1.01k views • 15 slides

According to WHO: 130 150 million people globally infected with HCV chronically High

RATIONAL DRUG DISCOVERY OF RATIONAL DRUG DISCOVERY OF POTENTIAL HCV HELICASE POTENTIAL HCV HELICASE POTENTIAL HCV HELICASE POTENTIAL HCV HELICASE INHIBITORS INHIBITORS by CH Heh According to WHO: 130 150 million people globally

142 views • 3 slides

Piloting HCV GHOST in Michigan www.michigan.gov/hepatitis November 29, 2017 Joe Coyle, MPH

Piloting HCV GHOST in Michigan www.michigan.gov/hepatitis November 29, 2017 Joe Coyle, MPH Outline MDHHS HCV Surveillance Basics of HCV GHOST Example of GHOST in Action Implications for Public Health Surveillance MDHHS HCV

458 views • 34 slides

Croatian perspective cost effectiveness analysis of interferon free therapy for chronic HCV

Croatian perspective cost effectiveness analysis of interferon free therapy for chronic HCV Neven Lovrinov, MSc.Pharm Terminal d.o.o. Croatia HCV treatment cost 2014 hot topic in media SVR rates in HCV Treatment Regimen Treatment

438 views • 39 slides

HCV: Basic virology, drug targets and -resistance Volker Lohmann

HCV: Basic virology, drug targets and -resistance Volker Lohmann http://www.molecular-virology.uni-hd.de Genetic diversity of HCV Genetic diversity of HCV 7 genotypes, subtypes quasispecies 20-25% difference 31-33% difference Simmonds

798 views • 40 slides

EBLL Response in HCV Units Segment 1: The Basics EBLL Response in in HCV Units Segment 1:

EBLL Response in HCV Units Segment 1: The Basics EBLL Response in in HCV Units Segment 1: The basics Segment 2: Index units Segment 3: Other covered units Key Acronyms LSHR: Lead Safe Housing Rule PHA: Public Housing Agency

344 views • 8 slides

HCV Vaccine Development Thomas Pietschmann TWINCORE Centre for Experimental and Clinical

HCV Vaccine Development Thomas Pietschmann TWINCORE Centre for Experimental and Clinical Infection Research A joint venture between Medical School Hannover and The Helmholtz Centre for Infection Research Preview 1.Do we need an HCV

2.22k views • 34 slides

AGM 28 November 2012 Milestones Achieved in 2011/2012 Clinical Programs: HCV

ASX:BIT AGM 28 November 2012 Milestones Achieved in 2011/2012 Clinical Programs: HCV Completed Phase 2a trial; positive data recorded HIV - Phase 2a trial commenced end 2011; data expected 1Q2013 HIV/HCV co-infected -

810 views • 25 slides

Phenotypic HCV-NS3-PI-Resistance Test Arevir Meeting, 11./12.04.2013 Daniel Rupp, MD Phenotypic

Phenotypic HCV-NS3-PI-Resistance Test Arevir Meeting, 11./12.04.2013 Daniel Rupp, MD Phenotypic HCV-NS3-PI-Resistance Assay Goal: Establishing a phenotypic NS3-PI resistance assay to characterize and monitor mutation development in patient

295 views • 18 slides

Drivers of HCV evolution - lessons from a single source outbreak Jrg Timm AREVIR 2017 What is

Drivers of HCV evolution - lessons from a single source outbreak Jrg Timm AREVIR 2017 What is the East-German Anti-D cohort? "Anti-D" November 1977 acute HCV?? Source February 1978 March 1978 Infusion of contaminated IgG to

336 views • 16 slides

HCV-Therapy 2015: V. Keitel Klinik fr Gastroenterologie, Hepatologie und Infektiologie

HCV-Therapy 2015: V. Keitel Klinik fr Gastroenterologie, Hepatologie und Infektiologie Direktor: Professor Dr. D. Hussinger Heinrich Heine Universitt Dsseldorf Dsseldorfer HCV cohort GT4 2014 GT4 GT3 GT1 GT1 GT3 GT2 GT2

333 views • 8 slides

Improvement of virological methods- Is it possible to predict the outcome of DAA treatment in HCV

Improvement of virological methods- Is it possible to predict the outcome of DAA treatment in HCV patients? Sandra Ciesek 06.05.2017 Outline - A new in vitro model to predict DAA response? - HCV genotyping Are all results correct? Folie 2

308 views • 17 slides

Rapid Management Plan Review for Greater Farallones National Marine Sanctuary February 27, 2019

Rapid Management Plan Review for Greater Farallones National Marine Sanctuary February 27, 2019 Why Management Plan Review? Adaptive Management Natural and human environment changes New opportunities New threats Transparency

367 views • 12 slides

SMART 2020 Germany Addendum. The ICT sector as the driving force on the way to sustained climate

SMART 2020 Germany Addendum. The ICT sector as the driving force on the way to sustained climate protection Enabled by Supported by SMART 2020 Germany Addendum Situation. Climate change is happening faster than was predicted just a few

344 views • 8 slides

ADDENDUM MATERIALS E. INFORMATION/DISCUSSION: Residency Programs Update Tony Redmond, Chief

HUMAN RESOURCES COMMITTEE MEETING January 9, 2019 5:00PM 6:30PM ADDENDUM MATERIALS E. INFORMATION/DISCUSSION: Residency Programs Update Tony Redmond, Chief Human Resources Officer Highland Emergency Medicine Highland Emergency Medicine

347 views • 16 slides

Addendum Optional Elements RCW 90.94.020 (4)(d)(i) The watershed plan may include: (i)

Okanogan Watershed Plan Addendum Optional Elements RCW 90.94.020 (4)(d)(i) The watershed plan may include: (i) Recommendations for modification to fees established under this subsection; Requires rulemaking process for Ecology

538 views • 5 slides

Local Control Accountability Plan and Federal Addendum Ani Silva June 6, 2019 8 State

Pacific Grove USD Local Control Accountability Plan and Federal Addendum Ani Silva June 6, 2019 8 State Priorities 1. Basic Services : Credentialed teachers, Instructional materials, Facilities in good repair 2. Implementation of State

169 views • 14 slides

Addendum to th the 20 2009 09 Environmental l Stu Study Report Online Public Information

Kerr Str Street at t Lak Lakeshore West Ra Rail il Cor orrid idor Gr Grade Se Separation Addendum to th the 20 2009 09 Environmental l Stu Study Report Online Public Information Centre September 12, 2019 Welc lcome Welcome

160 views • 12 slides

FY20 21 RESTATEMENT Budget Agency of Commerce and SeCretAry Community Development Lindsay

FY20 21 RESTATEMENT Budget Agency of Commerce and SeCretAry Community Development Lindsay Kurrle Deputy SeCretAry ted Brady AUGUST 20 20 Agenc ency of C Commer erce e & C Community SUMMARY & HIGHLIGHTS Dev evel elopment

300 views • 8 slides

Advancing patient-centred access to medicines in partnership with healthcare systems EMAs

Advancing patient-centred access to medicines in partnership with healthcare systems EMAs core recommendations Human Stakeholders Workshop Presented by Michael Berntgen on 24 October 2018 Head of Department, Product Development Scientific

504 views • 12 slides

More recommend

Explore More Topics

Stay informed with curated content and fresh updates.

animals pets art culture automotive transportation business finance computer internet construction architecture education-career electronics communication

HCV AMWMF Leitlinien Addendum Feb 2015 2014| Rolf Kaiser, Institut - PowerPoint PPT Presentation

HCV AMWMF Leitlinien Addendum Feb 2015 2014| Rolf Kaiser, Institut fr Virologie, Universitt zu Kln 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser

HCV Treatment : SOTA : where are we today ? Robert G. Gish MD San Diego ACCP 2012 Concepts in

HCV AND HEPATITIS HCV epidemiology and treatment failure Arevir meeting, 04.05.2019 | Saleta

HCV NS3/4A protease inhibitors for the treatment of HCV infected patients TMC435 Oliver

POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant

Geno2pheno[HCV] - Past, Present & Future Developments Bastian Beggel Max-Planck-Institute

According to WHO: 130 150 million people globally infected with HCV chronically High

Piloting HCV GHOST in Michigan www.michigan.gov/hepatitis November 29, 2017 Joe Coyle, MPH

Croatian perspective cost effectiveness analysis of interferon free therapy for chronic HCV

HCV: Basic virology, drug targets and -resistance Volker Lohmann

EBLL Response in HCV Units Segment 1: The Basics EBLL Response in in HCV Units Segment 1:

HCV Vaccine Development Thomas Pietschmann TWINCORE Centre for Experimental and Clinical

AGM 28 November 2012 Milestones Achieved in 2011/2012 Clinical Programs: HCV

Phenotypic HCV-NS3-PI-Resistance Test Arevir Meeting, 11./12.04.2013 Daniel Rupp, MD Phenotypic

Drivers of HCV evolution - lessons from a single source outbreak Jrg Timm AREVIR 2017 What is

HCV-Therapy 2015: V. Keitel Klinik fr Gastroenterologie, Hepatologie und Infektiologie

Improvement of virological methods- Is it possible to predict the outcome of DAA treatment in HCV

Rapid Management Plan Review for Greater Farallones National Marine Sanctuary February 27, 2019

SMART 2020 Germany Addendum. The ICT sector as the driving force on the way to sustained climate

ADDENDUM MATERIALS E. INFORMATION/DISCUSSION: Residency Programs Update Tony Redmond, Chief

Addendum Optional Elements RCW 90.94.020 (4)(d)(i) The watershed plan may include: (i)

Local Control Accountability Plan and Federal Addendum Ani Silva June 6, 2019 8 State

Addendum to th the 20 2009 09 Environmental l Stu Study Report Online Public Information

FY20 21 RESTATEMENT Budget Agency of Commerce and SeCretAry Community Development Lindsay

Advancing patient-centred access to medicines in partnership with healthcare systems EMAs

Explore More Topics

Sambuz

Useful Links

Newsletter

Mail Us

HCV AMWMF Leitlinien Addendum Feb 2015 2014| Rolf Kaiser, Institut - PowerPoint PPT Presentation

HCV AMWMF Leitlinien Addendum Feb 2015 2014| Rolf Kaiser, Institut fr Virologie, Universitt zu Kln 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser 2014| Rolf Kaiser

HCV Treatment : SOTA : where are we today ? Robert G. Gish MD San Diego ACCP 2012 Concepts in

HCV AND HEPATITIS HCV epidemiology and treatment failure Arevir meeting, 04.05.2019 | Saleta

HCV NS3/4A protease inhibitors for the treatment of HCV infected patients TMC435 Oliver

POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant

Geno2pheno[HCV] - Past, Present &amp; Future Developments Bastian Beggel Max-Planck-Institute

According to WHO: 130 150 million people globally infected with HCV chronically High

Piloting HCV GHOST in Michigan www.michigan.gov/hepatitis November 29, 2017 Joe Coyle, MPH

Croatian perspective cost effectiveness analysis of interferon free therapy for chronic HCV

HCV: Basic virology, drug targets and -resistance Volker Lohmann

EBLL Response in HCV Units Segment 1: The Basics EBLL Response in in HCV Units Segment 1:

HCV Vaccine Development Thomas Pietschmann TWINCORE Centre for Experimental and Clinical

AGM 28 November 2012 Milestones Achieved in 2011/2012 Clinical Programs: HCV

Phenotypic HCV-NS3-PI-Resistance Test Arevir Meeting, 11./12.04.2013 Daniel Rupp, MD Phenotypic

Drivers of HCV evolution - lessons from a single source outbreak Jrg Timm AREVIR 2017 What is

HCV-Therapy 2015: V. Keitel Klinik fr Gastroenterologie, Hepatologie und Infektiologie

Improvement of virological methods- Is it possible to predict the outcome of DAA treatment in HCV

Rapid Management Plan Review for Greater Farallones National Marine Sanctuary February 27, 2019

SMART 2020 Germany Addendum. The ICT sector as the driving force on the way to sustained climate

ADDENDUM MATERIALS E. INFORMATION/DISCUSSION: Residency Programs Update Tony Redmond, Chief

Addendum Optional Elements RCW 90.94.020 (4)(d)(i) The watershed plan may include: (i)

Local Control Accountability Plan and Federal Addendum Ani Silva June 6, 2019 8 State

Addendum to th the 20 2009 09 Environmental l Stu Study Report Online Public Information

FY20 21 RESTATEMENT Budget Agency of Commerce and SeCretAry Community Development Lindsay

Advancing patient-centred access to medicines in partnership with healthcare systems EMAs

Explore More Topics

Sambuz

Useful Links

Newsletter

Mail Us

Geno2pheno[HCV] - Past, Present & Future Developments Bastian Beggel Max-Planck-Institute